Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy
- PMID: 17848842
- DOI: 10.1007/BF03346353
Looking beyond low bone mineral density: multiple insufficiency fractures in a woman with post-menopausal osteoporosis on alendronate therapy
Abstract
Insufficiency fractures occur most commonly in the pelvic girdle and in the sacrum, followed by the tibia and the femoral neck. Insufficiency fractures of the femoral diaphyses are rare, with only few reported cases in the literature. The strongest associations exist with untreated osteoporosis. We describe an unusual case of multiple insufficiency fractures in a 73-yr-old Chinese woman who presented with a 10-month history of bilateral groin pain and difficulty with walking in the absence of trauma, diagnosed 18 months following the commencement of anti-resorptive therapy with alendronate. The pathogenesis of such insufficiency fractures is poorly understood, but next to low bone mineral density and micro-architectural damage likely involves other components such as changes in bone turnover and patient-related factors (e.g. non-compliance). This case report and review of the literature draws attention to some of the challenges in the diagnosis and management of such rare insufficiency fractures.
Similar articles
-
Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report.J Orthop Sci. 2002;7(6):707-12. doi: 10.1007/s007760200126. J Orthop Sci. 2002. PMID: 12486478
-
Cost-effectiveness of vertebral fracture assessment to detect prevalent vertebral deformity and select postmenopausal women with a femoral neck T-score>-2.5 for alendronate therapy: a modeling study.J Clin Densitom. 2006 Apr-Jun;9(2):133-43. doi: 10.1016/j.jocd.2005.11.004. Epub 2006 Apr 18. J Clin Densitom. 2006. PMID: 16785071
-
Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.J Clin Pharm Ther. 2016 Oct;41(5):519-23. doi: 10.1111/jcpt.12429. Epub 2016 Jul 21. J Clin Pharm Ther. 2016. PMID: 27440710 Clinical Trial.
-
[Diphosphonates: and alternative to estrogen therapy in postmenopausal osteoporosis. Experience with alendronate].Minerva Ginecol. 1996 Jun;48(6):263-72. Minerva Ginecol. 1996. PMID: 8927288 Review. Italian.
-
Etidronate and alendronate in the treatment of postmenopausal osteoporosis.Ann Pharmacother. 1999 May;33(5):587-99. doi: 10.1345/aph.18212. Ann Pharmacother. 1999. PMID: 10369624 Review.
Cited by
-
Review: epidemiology and pathophysiology of atypical femur fractures.Curr Osteoporos Rep. 2014 Mar;12(1):65-73. doi: 10.1007/s11914-014-0198-z. Curr Osteoporos Rep. 2014. PMID: 24526234 Review.
-
Fragility fractures of the hip and femur: incidence and patient characteristics.Osteoporos Int. 2010 Mar;21(3):399-408. doi: 10.1007/s00198-009-0962-6. Epub 2009 May 30. Osteoporos Int. 2010. PMID: 19484169
-
Management of osteoporosis among the elderly with other chronic medical conditions.Drugs Aging. 2012 Jul 1;29(7):549-64. doi: 10.2165/11599620-000000000-00000. Drugs Aging. 2012. PMID: 22715862 Free PMC article. Review.
-
Safety of long-term bisphosphonate therapy for the management of osteoporosis.Drugs. 2011 Apr 16;71(6):791-814. doi: 10.2165/11585470-000000000-00000. Drugs. 2011. PMID: 21504254 Review.
-
Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.Osteoporos Int. 2012 Jun;23(6):1769-78. doi: 10.1007/s00198-011-1793-9. Osteoporos Int. 2012. PMID: 21975558 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical